Watson files application for Lidoderm generic
CHADDS FORD, Pa. Watson Pharmaceuticals has filed for regulatory approval of a generic version of a pain drug made by Endo Pharmaceuticals, Endo announced Tuesday.
Endo said it had received notice that Watson had filed an application for a generic version of Lidoderm (lidocaine), a topical patch used to treat pain related to postherpetic neuralgia.
While not specifying that it would file a patent infringement suit against Watson, which it can do under the terms of the Hatch-Waxman Act of 1984, Endo said it would “vigorously defend” its intellectual property rights. The patent for Lidoderm expires in October 2015, according to the Food and Drug Administration’s Orange Book database.